Form 4: Beta Bionics Chief Commercial Officer Sells Shares for Tax Obligations

Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc., sold 868 shares of common stock on June 2, 2025, to cover tax withholding obligations related to the vesting of restricted stock units.

Summary

• Mark Hopman, the Chief Commercial Officer of Beta Bionics, Inc. (BBNX), reported the sale of common stock.
• The transactions occurred on June 2, 2025, and involved three separate sales of shares.
• A total of 238 shares were sold at a weighted average price of $17.028 per share, with prices ranging from $16.62 to $17.56.
• An additional 551 shares were sold at a weighted average price of $18.1489 per share, with prices ranging from $17.62 to $18.60.
• A final block of 79 shares was sold at a weighted average price of $18.691 per share, with prices ranging from $18.69 to $18.73.
• The total number of shares sold across these transactions is 868.
• The purpose of these sales was explicitly stated as covering tax withholding obligations associated with the vesting of restricted stock units.
• Following these reported transactions, Mark Hopman beneficially owns 34,132 shares of common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the reported transactions are routine, non-discretionary sales for tax purposes related to executive compensation, which is a common occurrence and does not typically indicate a change in company fundamentals or executive confidence.

Positives

• The sale of shares was non-discretionary, specifically to cover tax withholding obligations, which is a common and routine practice for executives receiving equity compensation.
• The transaction indicates the vesting of restricted stock units, implying that the executive is receiving compensation as planned.

Negatives

• The sale results in a slight reduction in the direct beneficial ownership of common stock by a key executive, from 34,762 shares to 34,132 shares after the first reported transaction, and then further to 34,132 shares after all reported transactions.

Risks

• While the sale is for tax purposes, any reduction in insider ownership, even for routine reasons, can sometimes be misinterpreted by the market if the context is not fully understood.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook, as its sole purpose is to report insider transactions.

Management Comments

• Mark Hopman, through his attorney-in-fact, stated that 'The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.'

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction, common across all publicly traded companies. It reflects the standard practice of executives selling a portion of vested equity awards to cover tax liabilities, rather than a discretionary sale based on market sentiment or company performance. Such transactions are a normal part of executive compensation plans involving restricted stock units.

Stakeholder Impact

• Shareholders: The impact is minimal as these are routine, non-discretionary sales for tax purposes, not indicative of a lack of confidence. The slight reduction in insider ownership is offset by the normal course of executive compensation.
• Employees: No direct impact mentioned, but it reflects the standard process of equity compensation for executives.

Key Dates

Recommendation

Keywords

Beta Bionics, BBNX, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, Tax Withholding, Executive Compensation, Mark Hopman, Chief Commercial Officer